You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科華生物(002022.SZ)業績快報:2020年度淨利潤升232.56%至6.73億元
格隆匯 04-06 17:53

格隆匯 4 月 6日丨科華生物(002022.SZ)發佈2020年度業績快報,實現營業總收入42.04億元,同比增長74.12%;利潤總額13.57億元,同比增長312.90%;歸屬於上市公司股東的淨利潤6.73億元,同比增長232.56%;基本每股收益1.3117元。

2020年度,公司始終圍繞發展戰略目標,專注主營業務,聚焦優勢領域,堅定有序開展各項工作,堅持技術創新,進一步豐富公司產品線,深化分子診斷業務的戰略佈局,提升產品服務品質。年初受新冠病毒肺炎疫情影響,國內醫院的常規門急診就診人數明顯下降,公司傳統生化免疫業務收入下降。隨着國內疫情得到有效控制以及各地復工復產的推進,公司傳統生化免疫業務逐步恢復。時,公司積極把握因新冠病毒肺炎疫情激增的分子診斷業務市場需求,充分發揮在分子診斷領域的技術積澱和產品優勢,進一步提升分子臨牀產品在終端市場的銷售增長。報吿期內,公司分子診斷業務中自產核酸提取儀器和試劑、核酸擴增儀器和試劑的銷售收入均實現大幅度增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account